While much research focuses on oncogenic proteins and signaling pathways in aggressive cancers, fewer studies investigate how normal cells transform into ...

The University of Virginia School of Medicine's Harald Sontheimer, PhD, and Stanford's Michelle Monje, MD, PhD, have received ...

A new drug was shown to significantly reduce tumor growth in lab studies by up to 77% for melanoma and colorectal cancers.

A study led by Dr. Li Chuanyun from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences ...

New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in ...

Lab study findings increase understanding of the molecular mechanisms underpinning vitamin D deficiency and highlight SDR42E1 ...

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found ...

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for ...

Interestingly, when telomerase was turned off in endothelial cells, which cover blood vessels, tumors shrank and became poorly supplied with blood, leading to oxygen deprivation. In the case of ...

Volume 17, Issue 6, on June 5, 2025, titled “Senescence caused by telomerase inactivation in myeloid, mesenchymal, and endothelial cells has distinct effects on cancer progression.” ...

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...